The images or other third party material in this article are included in the articles Creative Commons licence, unless indicated otherwise in a credit line to the material
Key benefits Why people compare it 1 14.9% mean body weight reduction demonstrated in STEP 1 trial (N=1,961) 2 20% reduction in major adverse cardiovascular events in SELECT trial (N=17,604) 3 Significant reduction in appetite and food cravings via hypothalamic POMC/CART activation 4 Improved glycemic control with glucose-dependent insulin secretion potentiation 5 Once-weekly dosing enabled by 165-hour plasma half-life and albumin binding 6 86.4% of STEP 1 participants achieved at least 5% body weight loss 7 Demonstrated NAFLD/NASH improvement with reduction in liver fat content 8 Well-characterized safety profile from over 30,000 participants across STEP and SELECT programs Deep research Semaglutide (chemical name: N-epsilon26-[2-(2-[2-(2-[2-(2-((S)-2-carboxy-3-((1S,2R)-3-carboxy-1-(carboxymethyl-carbamoyl)-propylcarbamoyl)-propionylamino)-ethoxy)-ethoxy)-acetylamino]-ethoxy)-ethoxy)-acetyl]-[Aib8,Arg34]-GLP-1-(7-37)-peptide) is a 39-amino-acid peptide with a molecular weight of 4,113.58 Da
Most individuals see the most dramatic changes over three to six months of use, along with healthy lifestyle modifications
[5] A solution that appears normal may have significantly reduced potency or may contain degradation products with unknown safety profiles
The ADA doesnt recommend [archived link] compounded GLP-1 RAs due to uncertainty about their content, safety, quality, and effectiveness. The FDA has warned [archived link] about counterfeit and harmful GLP-1 RAs being sold online
verify current pricing and terms on the official page before purchase
